{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8"],"submitter":["Sperle I"],"funding":["Deutsches Zentrum für Infektionsforschung","Bundesministerium für Gesundheit"],"pubmed_abstract":["<b>Background:</b> One of the five strategic directions in the World Health Organization global health sector strategy on viral hepatitis 2016-2021 is to generate strong strategic information for focused action to understand the viral hepatitis epidemic and focus the response. Knowledge of national prevalence is a cornerstone of strategic information. Germany is considered to be a low prevalence country for viral hepatitis B, C, and D, however the prevalence is likely to be higher among at-risk groups. <b>Methods:</b> The aim of this work was to give a detailed overview of the prevalence of viral hepatitis B (HBsAg, anti-HBc), C (anti-HCV, HCV RNA), and D (anti-HDV, HDV RNA) in different population groups in Germany. Therefore, we analyzed the results of a comprehensive literature search o"],"journal":["Frontiers in public health"],"pagination":["424"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7493659"],"repository":["biostudies-literature"],"pubmed_title":["Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review."],"pmcid":["PMC7493659"],"pubmed_authors":["Sperle I","Beermann S","Sarma N","Thamm R","Zimmermann R","Bremer V","Dudareva S","Cornberg M","Wedemeyer H","Steffen G","Simeonova Y","Leendertz SA"],"additional_accession":[]},"is_claimable":false,"name":"Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review.","description":"<b>Background:</b> One of the five strategic directions in the World Health Organization global health sector strategy on viral hepatitis 2016-2021 is to generate strong strategic information for focused action to understand the viral hepatitis epidemic and focus the response. Knowledge of national prevalence is a cornerstone of strategic information. Germany is considered to be a low prevalence country for viral hepatitis B, C, and D, however the prevalence is likely to be higher among at-risk groups. <b>Methods:</b> The aim of this work was to give a detailed overview of the prevalence of viral hepatitis B (HBsAg, anti-HBc), C (anti-HCV, HCV RNA), and D (anti-HDV, HDV RNA) in different population groups in Germany. Therefore, we analyzed the results of a comprehensive literature search o","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2025-05-29T19:38:23.496Z","creation":"2025-05-29T19:38:23.496Z"},"accession":"S-EPMC7493659","cross_references":{"pubmed":["33014960"],"doi":["10.3389/fpubh.2020.00424"]}}